![]() ![]() It also permits us to refocus on our existing portfolio of products offered to veterinary clinics and pet owners in the United States, and maximize our growth potential, either organically through future launches, or through acquisitions. Divesting these brands is an opportunity for Virbac to significantly deleverage the Group. These synergies on historical products have not materialized due to the Bridgeton manufacturing site temporary interruption, while the number of brands in the parasiticide segment has grown over the recent years. At the time of the acquisition, Virbac was expecting a high leverage from the synergies on the historical ranges through the access to new large veterinary clinics and the more than doubling of the sales force. In the United States, SENTINEL ® FLAVOR TABS ® and SENTINEL ® SPECTRUM ® have reached total revenues of around US $70 million in 2019. In relation with the transaction, Virbac will keep its commercial structure substantially unchanged, and will continue to manufacture SENTINEL ® SPECTRUM ® at its Bridgeton, Missouri site for the next ten years. Under the terms of this agreement, Virbac will divest a combination of titles and rights for the United States on trademarks, marketing authorizations, patents, know-how, and other assets, related to two parasiticides for dogs: SENTINEL ® FLAVOR TABS ® and SENTINEL ® SPECTRUM ®. These assets were acquired in early 2015 from Eli Lilly. Virbac announces that it has entered into an agreement with MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), to divest veterinary products currently marketed in the United States under the SENTINEL ® brands by Virbac, for US $400 million in an all-cash deal subject to customary post-closing adjustments. ![]()
0 Comments
Leave a Reply. |